(Q58447645)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

title

Targeting the intestinal L-cell for obesity and type 2 diabetes treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

Jens Juul Holst

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

author name string

Nicolai Jacob Wewer Albrechtsen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

Rune Ehrenreich Kuhre

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

publication date

9 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

Expert review of endocrinology & metabolism

22 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

page(s)

61-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

Global obesity: trends, risk factors and policy implications

22 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Pharmacologic treatment options for obesity: what is old is new again

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effective weight management practice: a review of the lifestyle intervention evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Preservation of β-cell function: the key to diabetes prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Incretin hormones and the satiation signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Obesity and appetite control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The role of leptin in the control of insulin-glucose axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The role of gut hormones and the hypothalamus in appetite regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The defence of body weight: a physiological basis for weight regain after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Gastrointestinal satiety signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Brain-derived neurotrophic factor (BDNF) in the hypothalamic ventromedial nucleus increases energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Transcription factors in the development of medial hypothalamic structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Gut hormones and the regulation of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The sensory circumventricular organs: brain targets for circulating signals controlling ingestive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effect of peptide YY3-36 on food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Satiety effects of a physiological dose of cholecystokinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Unsulfated cholecystokinin: An overlooked hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Human distribution and release of a putative new gut hormone, peptide YY

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

CCK, PYY and PP: the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Unraveling oxyntomodulin, GLP1's enigmatic brother

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Oxyntomodulin : a novel potential treatment for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Mammalian pancreatic preproglucagon contains three glucagon-related peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

The role of neurotensin in physiologic and pathologic processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Activation and functional characterization of the mosaic receptor SorLA/LR11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Nutrient detection by incretin hormone secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Stimulation of incretin secretion by dietary lipid: is it dose dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

A gut feeling for obesity: 7TM sensors on enteroendocrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

An anorexic lipid mediator regulated by feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Molecular mechanisms underlying nutrient detection by incretin-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17446651.2014.862152

10.1586/17446651.2014.862152

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30743739%20AND%20SRC:MED&resulttype=core&format=json

22 April 2020

1 reference